|
 |
| home > pmps > autumn 2003 > preventative medicine - how advances in technology can protect the integrity of the supply chain |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
Countering the threat of biological terrorism, preventing the misdirection of drugs and stopping counterfeit goods entering the legitimate supply chain are currently some of the most important and pressing issues for the pharmaceutical industry.
According to the World Health Organization (WHO), up to one in 10 of all the pharmaceuticals in the market today could be counterfeit, implying potentially lethal consequences for millions of consumers. A patient's return to health will be impaired if they do not receive the prescribed drugs for their particular illness or disorder. Worse still, if counterfeit drugs contain harmful agents, the health of patients could be damaged further. There is always the possibility that a patient may be allergic to the chemicals in a counterfeit drug. Participants in the pharmaceutical supply chain are now seriously reviewing their corporate strategies to ensure traceability, compliance, due diligence and risk mitigation can be delivered through their enterprise resource planning (ERP) based software business applications.
Manufacturers and distributors of pharmaceuticals can further mitigate the risks posed by counterfeit goods entering the legitimate supply chain by introducing electronic forms of identification and authentication. Hospitals, dispensaries and pharmacies can utilise electronic authentication to ensure they only stock and administer genuine products, which comply with relevant government safety standards.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
MipTec, October 14 – 16, 2008, Switzerland
MipTec about to take off by joining forces between Life Sciences Week, ALL-SystemsX.ch-Day, & Jobvector.com
More info >> |
|
 |
